|
Volumn 6, Issue 2, 2005, Pages 116-119
|
Fluocinolone acetonide ophthalmic - Bausch & Lomb: Fluocinolone acetonide envision TD implant
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
FLUOCINOLONE ACETONIDE;
ORPHAN DRUG;
ARTICLE;
ASIA;
AUSTRALIA;
CANADA;
CATARACT;
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
DIABETES MELLITUS;
DOSE RESPONSE;
DRUG DELIVERY SYSTEM;
DRUG INDICATION;
DRUG INDUSTRY;
EQUIPMENT DESIGN;
EYE DISEASE;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
GLAUCOMA;
HONG KONG;
HUMAN;
IMPLANT;
INDIA;
INTRAOCULAR HYPERTENSION;
LICENCE;
MEDICAL SOCIETY;
META ANALYSIS;
PHILIPPINES;
POSTERIOR EYE CHAMBER;
PRIORITY JOURNAL;
RESPONSIBILITY;
RETINA MACULA AGE RELATED DEGENERATION;
RETINA MACULA EDEMA;
RETINA NEOVASCULARIZATION;
SINGAPORE;
SUBRETINAL NEOVASCULARIZATION;
SYSTEMATIC REVIEW;
TREATMENT OUTCOME;
UNITED STATES;
UVEITIS;
VISUAL ACUITY;
VITREOUS HEMORRHAGE;
ANTI-INFLAMMATORY AGENTS;
CLINICAL TRIALS, PHASE III;
DRUG IMPLANTS;
DRUGS, INVESTIGATIONAL;
FLUOCINOLONE ACETONIDE;
HUMANS;
UVEITIS;
|
EID: 16844362809
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200506020-00007 Document Type: Article |
Times cited : (24)
|
References (6)
|